郭爱桃, 李岩密, 韦立新, 宋欣. 腹膜假黏液瘤的临床病理学特征分析[J]. 解放军医学院学报, 2012, 33(9): 929-932. DOI: 10.3969/j.issn.1005-1139.2012.09.012
引用本文: 郭爱桃, 李岩密, 韦立新, 宋欣. 腹膜假黏液瘤的临床病理学特征分析[J]. 解放军医学院学报, 2012, 33(9): 929-932. DOI: 10.3969/j.issn.1005-1139.2012.09.012
GUO Ai-tao, LI Yan-mi, WEI Li-xin, SONG Xin. Clinical and pathological features of pesudomyxoma peritonei[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2012, 33(9): 929-932. DOI: 10.3969/j.issn.1005-1139.2012.09.012
Citation: GUO Ai-tao, LI Yan-mi, WEI Li-xin, SONG Xin. Clinical and pathological features of pesudomyxoma peritonei[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2012, 33(9): 929-932. DOI: 10.3969/j.issn.1005-1139.2012.09.012

腹膜假黏液瘤的临床病理学特征分析

Clinical and pathological features of pesudomyxoma peritonei

  • 摘要: 目的 评价腹膜假黏液瘤(pseudomyxoma peritonei,PMP)的临床病理学特征。 方法 收集我院收治的92例PMP的临床、病理及随访资料,将92例分为腹膜弥漫性黏液腺瘤病(disseminated peritoneal adenomucinosis,DPAM)、腹膜黏液腺癌病(peritoneal mucinous carcinomatosis,PMCA)以及交界性腹膜弥漫性黏液腺癌病(PMCA with intermediate or discordant features,PMCA-I/D)三组,采用Kaplan meier法计算整体生存率,并分析预后相关因素。 结果 92例中3、5和10年的整体生存率分别为74.0%、67.4%和49.1%,22例死亡,中位生存期124.0月;平均年龄51.9岁(22-76岁)。DPAM组49例,中位生存期312.9月,8例(16.3%)死亡,3、5及10年生存率为97.0%、80.0%及67.0%。PMCA-I/D组26例,中位生存期84.0月,6例(23.1%)死亡,3年、5年及10年生存率分别为80.0%、67.0%及50.0%。PMCA组17例,中位生存期31.7月,其中8例(47.1%)死亡,3及5年生存率为65.0%及28.0%,最长随访时间为108个月。DPAM组预后最好,PMCA组预后最差,3组间生存率差异具有显著性(P=0.001)。年龄、阑尾肿瘤、实质脏器受累与患者生存期关系密切,<40岁者预后最差(P=0.001)。 结论 在病理诊断中应采用DPAM、PMCA和PMCA-I/D对PMP进行分类,废弃PMP这一模棱两可的名称;虽然大部分病例病理形态为良性或低度恶性,患者10年生存率仍较低;病理学分类、年龄、阑尾肿瘤及实质脏器累及为临床预后相关因素,<40岁、伴有阑尾黏液腺癌和实质脏器受累者预后更差。

     

    Abstract: Objective To assess the clinical and pathological features of pseudomyxoma peritonei(PMP). Methods Clinical,pathological and follow-up data about 92 PMP patients admitted to our hospital were retrospectively analyzed.The patients were divided into disseminated peritoneal adenomucinosis(DPAM) group(n=49),peritoneal mucinous carcinomatosis(PMCA) group(n=17),and PMCA with intermediate or discordant features(PMCA-I/D) group(n=26).Their survival rate was calculated with the Kaplan-Meier method and related factors for their prognosis were analyzed. Results Twenty-two of the 92 PMP patients died at the mean age of 51.9 years(22-76 years) with a median survival time of 124.0 months and their 3-,5-,and 10-year survival rate was 74.0%,67.0% and 49.0%,respectively.Eight patients in DPAM group died with a median survival time of 312.9 months and their 3-,5-,and 10-year survival rate was 97.0%,80.0%,and 67.0%,respectively.Six patients in PMCA-I/D group died with a median survival time of 84.0 months and their 3-,5-,and 10-year survival rate was 80.0%,67.0%,and 50.0%,respectively.Eight patients in PMCA group died with a median survival time of 31.7 months and their 3-and 5-year survival rate was 65.0% and 28.0%,respectively.The longest follow-up time was 108 months with the best prognosis observed in DPAM group and the poorest prognosis observed in PMCA group(P=0.001).The survival time of the patients,especially those with their age <40 years,was closely related with their age,appendiceal tumor and parenchymal organ involvement. Conclusion PMP should be used as DPAM,PMCA and PMCA-I/D in its pathological diagnosis.Although the pathological morphology of most PMP patients is benign or low malignant,their 10-year survival rate is rather low.The prognosis of PMP patients,especially those with their age <40 years,is closely related with their age,appendiceal tumor and parenchymal organ involvement.

     

/

返回文章
返回